Начало › Лимфом на Бъркит › Тексас › Houston
Клинични проучвания за Лимфом на Бъркит в Houston, TX
21 проучвания за Лимфом на Бъркит търсят участници в обекти в и около Houston (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Набиране на участнициФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Набиране на участнициФаза 3
- Houston Methodist Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Набиране на участнициНаблюдателно проучване
- Texas Children's Hospital, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Набиране на участнициФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Набиране на участнициФаза 3
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Набиране на участнициФаза 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Набиране на участнициФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Набиране на участнициФаза 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Набиране на участнициФаза 2
- Baylor Texas Children's Hospital, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Набиране на участнициФаза 1/2
- Research Site, Houston
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Набиране на участнициФаза 2
- M D Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Набиране на участнициФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Набиране на участнициФаза 1/2
- M D Anderson Cancer Center, Houston
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Набиране на участнициФаза 1/2
- Research Site, Houston
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Набиране на участнициФаза 2
- M D Anderson Cancer Center, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Набиране на участнициФаза 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Проучвания за Лимфом на Бъркит в други градове
- Milwaukee, WI16 проучвания
- Philadelphia, PA16 проучвания
- New York City, NY14 проучвания
- Chicago, IL14 проучвания
- Cincinnati, OH12 проучвания
- Atlanta, GA12 проучвания
- Seattle, WA11 проучвания
- Boston, MA10 проучвания
- Durham, NC10 проучвания
- Aurora, CO10 проучвания
- Los Angeles, CA10 проучвания
- Kansas City, MO10 проучвания
Други проучвания в Houston
- Рак на белия дроб с недребноклетъчен тип145 проучвания
- Рак на гърдата126 проучвания
- Рак (всички видове)121 проучвания
- Метастатичен рак104 проучвания
- Колоректален рак102 проучвания
- Рак на яйчниците89 проучвания
- Остра миелоидна левкемия85 проучвания
- Рак на белия дроб78 проучвания
- Рак на простатата76 проучвания
- Ендометриален рак68 проучвания
- Рак на панкреаса61 проучвания
- Меланом59 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.